Cargando…

Effect of febuxostat on the level of malondialdehyde‐modified low‐density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study

BACKGROUND: Febuxostat is a selective xanthine oxidase inhibitor that reportedly exhibits antioxidant properties. We previously performed a multicentre, randomized controlled (PRIZE) study for vascular evaluation under uric acid (UA) control by febuxostat to investigate the progression of carotid le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teragawa, Hiroki, Tanaka, Atsushi, Fujii, Yuichi, Yoshida, Hisako, Ueda, Tomohiro, Nomura, Shuichi, Kadokami, Toshiaki, Koide, Hisashi, Saito, Makoto, Sano, Hiroaki, Bando, Yasuko K., Murohara, Toyoaki, Node, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270262/ https://www.ncbi.nlm.nih.gov/pubmed/36991567 http://dx.doi.org/10.1002/clc.24014

Ejemplares similares

Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study
por: Saito, Yuichi, et al.
Publicado: (2022)

Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study
por: Oyama, Jun-ichi, et al.
Publicado: (2016)

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study
por: Kusunose, Kenya, et al.
Publicado: (2021)

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
por: Maruhashi, Tatsuya, et al.
Publicado: (2022)

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
por: Sezai, Akira, et al.
Publicado: (2022)

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Blood Oxygen, Sleep Disordered Breathing, and Respiratory Instability in Patients With Chronic Heart Failure　― PROST Subanalysis ―
por: Tobushi, Tomoyuki, et al.
Publicado: (2019)

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study
por: Yamada, Hirotsugu, et al.
Publicado: (2017)

Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma
por: Barrios, Carlos H, et al.
Publicado: (2016)

Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
por: Yisireyili, Maimaiti, et al.
Publicado: (2017)

Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
por: Tanaka, Atsushi, et al.
Publicado: (2023)

Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricema
por: Nishizawa, Tohru, et al.
Publicado: (2015)

Febuxostat methanol solvate
por: Jiang, Qi-Ying, et al.
Publicado: (2011)

Febuxostat ethanol monosolvate
por: Gelbrich, Thomas, et al.
Publicado: (2020)

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience
por: Sulaiman, Narisa, et al.
Publicado: (2017)

Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study
por: Tanaka, Atsushi, et al.
Publicado: (2016)

Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study
por: Saito, Yuichi, et al.
Publicado: (2023)

Febuxostat and the Black Box Blues
por: Abeles, Aryeh M., et al.
Publicado: (2019)

Evaluation of Paraoxonase, Malondialdehyde, and Lipoprotein Levels in Patients with Asymptomatic Cholelithiasis
por: Atamer, Aytac, et al.
Publicado: (2014)

Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice
por: Nomura, Johji, et al.
Publicado: (2014)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
por: Oishi, Hideo, et al.
Publicado: (2020)

High-output Heart Failure Caused by a Tumor-related Arteriovenous Fistula: A Case Report and Literature Review
por: Tobe, Akihiro, et al.
Publicado: (2021)

Comparison of plasma lipoprotein profiles and malondialdehyde between hyperlipidemia dogs with/without treatment
por: Li, Gebin, et al.
Publicado: (2014)

Prize Presentations: ACHARI PRIZE
Publicado: (2021)

Malondialdehyde Level in the Cord Blood
por: Joob, Beuy, et al.
Publicado: (2012)

Efficacy and safety of febuxostat in elderly female patients
por: Mizuno, Tomohiro, et al.
Publicado: (2014)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application
por: Kraev, Krasimir Iliev, et al.
Publicado: (2023)

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
por: Hirai, Hiroyuki, et al.
Publicado: (2019)

Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2019)

The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
por: Ashtar, Mohannad, et al.
Publicado: (2020)

Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats
por: Shirakura, Takashi, et al.
Publicado: (2016)

Therapeutic Angiogenesis with Somatic Stem Cell Transplantation
por: Murohara, Toyoaki
Publicado: (2019)

Frequency and Clinical Impact of Family History of Coronary Artery Disease in Patients with Vasospastic Angina
por: Teragawa, Hiroki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dblntrktfsobh3k4ppftt9ueln